Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes
NCT05946785Phase 1Recruiting
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of ascorbic acid and ng-nitro-l-arginine methyl ester in microvascular dysfunction (MVD) (3 arms). Primary endpoints: Microvascular acetylcholine-mediated dilation at 4 hours and Microvascular insulin-mediated dilation at 4 hours. Started Jul 2023; status: recruiting.
02
Drugs
ascorbic acidng-nitro-l-arginine methyl ester
03
Conditions
microvascular dysfunction (MVD)
Beyond the preview
Go deeper on NCT05946785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05946785.